IL6R rs8192284: Understanding the Asp358Ala Variant
The rs8192284 variant is a common genetic change in the IL6R gene that results in an amino acid substitution known as p.Asp358Ala. This variant is widely studied for its role in increasing levels of the soluble interleukin-6 receptor in the blood and its potential influence on inflammatory pathways.
What each genotype means
Baseline risk profile
This genotype represents the baseline state for this variant in the context of studies examining melanoma risk. Research is limited and mixed, with some studies suggesting different risk associations compared to other genotypes; however, these findings are not definitive and should not be used to predict individual health outcomes.
The frequency of this genotype varies significantly by ancestry and is not uniformly documented across all global populations.
Potential increased risk association
Some research has observed an association between this heterozygous genotype and an increased risk for certain complex traits, such as melanoma, in specific study cohorts. Because this evidence is based on limited statistical associations, it does not imply a direct cause of disease and should be interpreted with caution.
This genotype is observed in various populations, though its specific prevalence depends on the underlying frequency of the A and C alleles in a given ancestral group.
Alternative risk profile
This genotype has been identified in association studies investigating susceptibility to complex traits. The clinical significance remains uncertain, and the observed associations are statistical in nature rather than diagnostic; therefore, this information should not be used to make medical decisions.
The prevalence of this genotype is dependent on the specific population, with frequencies varying widely across different global ancestral groups.
What is rs8192284?
The variant rs8192284 is a single nucleotide polymorphism (SNP) located within the IL6R gene on chromosome 1. This specific change involves the substitution of an adenine (A) for a cytosine (C), which leads to a non-synonymous change in the protein sequence where aspartic acid is replaced by alanine at position 358 (p.Asp358Ala). This site is located at the proteolytic cleavage point of the IL-6 receptor. Because of this location, the variant is considered functional; it enhances the shedding of the membrane-bound receptor, which increases the concentration of soluble IL-6 receptor (sIL-6R) circulating in the bloodstream. Researchers often use this variant as a genetic tool to study how the IL-6 signaling pathway functions in the human body.
The Role of the IL6R Gene
The IL6R gene provides instructions for making the interleukin-6 receptor protein. This receptor is a critical component of the immune system, allowing cells to respond to interleukin-6 (IL-6), a cytokine that plays a major role in inflammation and the body's response to infection or tissue damage. When IL-6 binds to its receptor, it triggers a signaling cascade that can either promote or regulate inflammatory responses. By altering the amount of soluble receptor available, the rs8192284 variant changes the extracellular environment of IL-6 signaling. This can influence processes like 'trans-signaling,' where the soluble receptor binds to IL-6 and activates cells that might not otherwise respond to the cytokine, or it may act as a buffer to modulate the overall inflammatory state.
Research Associations and Evidence
Scientific research has consistently linked the rs8192284 variant to measurable changes in blood biomarkers. Specifically, individuals carrying the C allele show significantly higher levels of soluble IL-6 receptor and, in some studies, lower levels of C-reactive protein (CRP) and fibrinogen. While these associations with biomarkers are strong and well-replicated, the clinical implications are more complex. Large-scale studies have investigated whether this variant influences the risk of conditions like type 2 diabetes or coronary heart disease. While some Mendelian randomization studies suggest a potential protective effect against certain cardiovascular outcomes, other research has found no significant association with chronic disease risk or longevity. The evidence remains nuanced, and the variant is primarily viewed as a tool for understanding biological mechanisms rather than a direct predictor of disease.
Population Frequency
The rs8192284 variant is considered a common polymorphism, though its frequency varies significantly across different ancestral groups. For example, research indicates that the minor allele frequency is approximately 35% in European populations, while it is notably lower, around 4%, in West African populations. Because it is common, it is frequently encountered in genetic studies and population-based health research. These frequency differences highlight the importance of considering ancestry when interpreting genetic data, as the prevalence of specific genotypes can differ widely depending on an individual's genetic background.
What This Information Means for You
Understanding your genotype for rs8192284 provides insight into how your body processes the IL-6 receptor, but it does not serve as a medical diagnosis. Because the variant's impact on health outcomes is complex and often context-dependent, it cannot be used to predict your personal risk for inflammatory diseases or to guide treatment decisions. If you have concerns about inflammatory conditions or are interested in how your genetics might relate to your health, the best course of action is to consult with a qualified healthcare provider or a genetic counselor. They can help you interpret your results within the context of your overall health history and current clinical guidelines. Never use genetic information to make changes to your medications or health regimen without professional medical supervision.
How common is this variant?
The rs8192284 variant is common, with a minor allele frequency of approximately 35% in European populations and about 4% in West African populations.
Frequently asked questions
Is rs8192284 a disease-causing mutation?
No, rs8192284 is a common genetic variant, not a disease-causing mutation. It is associated with changes in biomarker levels, such as the soluble IL-6 receptor, but it is not considered a direct cause of any specific medical condition.
Can I use this variant to predict my risk of inflammation?
No, this variant cannot be used to predict your personal risk of inflammatory diseases. While it influences biological pathways, many other genetic and environmental factors determine your overall health and inflammatory status.
Does this variant affect how I respond to medication?
Research into this variant often focuses on its role in biological pathways similar to those targeted by certain anti-inflammatory drugs. However, you should never use this information to make decisions about your medication; always discuss your treatment plan with your doctor or pharmacist.
Why do some studies show different results for this variant?
Genetic associations can vary due to differences in study design, the populations being studied, and the specific health outcomes being measured. Because the effects of this variant are subtle and influenced by many factors, results can appear inconsistent across different research papers.
Sources & further reading
Educational information only, last refreshed 10/26/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs8192284?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in IL6R
Synonymous polymorphism in IL6R often studied in the context of inflammatory signaling; however, the primary functional variant in this gene is rs2228145 (Asp358Ala).
An intronic variant in the IL6R gene associated with systemic inflammatory signaling, reduced risk of certain cardiovascular conditions, and parental lifespan.
This variant is a functional polymorphism in the IL6R gene associated with altered levels of soluble interleukin-6 receptor and C-reactive protein, influencing inflammatory response.
This SNP is associated with variations in C-reactive protein (CRP) levels and is considered a marker for systemic inflammation and cardiovascular risk.
This variant is associated with soluble IL-6 receptor levels and is linked to inflammatory markers and cardiovascular disease risk.
Functional missense variant (p.Asp358Ala) that enhances proteolytic shedding of IL-6R to elevate soluble receptor levels while dampening classical IL-6 inflammatory signaling, conferring protection against coronary heart disease.